105 related articles for article (PubMed ID: 25605021)
21. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
22. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.
Gökmen-Polar Y; Mehta R; Tuzmen S; Mousses S; Thorat MA; Sanders KL; Turbin D; Leung S; Huntsman DG; Sledge GW; Badve S
Breast Cancer Res Treat; 2010 Nov; 124(2):327-35. PubMed ID: 20099025
[TBL] [Abstract][Full Text] [Related]
23. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
25. Development of Herceptin resistance in breast cancer cells.
Kute T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP
Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
[TBL] [Abstract][Full Text] [Related]
26. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.
Cadenas C; Franckenstein D; Schmidt M; Gehrmann M; Hermes M; Geppert B; Schormann W; Maccoux LJ; Schug M; Schumann A; Wilhelm C; Freis E; Ickstadt K; Rahnenführer J; Baumbach JI; Sickmann A; Hengstler JG
Breast Cancer Res; 2010; 12(3):R44. PubMed ID: 20584310
[TBL] [Abstract][Full Text] [Related]
27. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
28. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
29. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
30. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.
Fink-Retter A; Gschwantler-Kaulich D; Hudelist G; Mueller R; Kubista E; Czerwenka K; Singer CF
Oncol Rep; 2007 Aug; 18(2):299-304. PubMed ID: 17611648
[TBL] [Abstract][Full Text] [Related]
31. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
32. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
33. INFLUENCE OF miR-373 ON THE INVASION AND MIGRATION OF BREAST CANCER AND THE EXPRESSION LEVEL OF TARGET GENES TXNIP.
Wang JG; Zhang LK; Chen YB; Zhang T; Yuan PF; Liu DC
J Biol Regul Homeost Agents; 2015; 29(2):367-72. PubMed ID: 26122224
[TBL] [Abstract][Full Text] [Related]
34. RNA sequence analyses of r-Moj-DM treated cells: TXNIP is required to induce apoptosis of SK-Mel-28.
McBride TD; Andrew U; Ly N; Soto JG
Toxicon; 2016 Oct; 121():1-9. PubMed ID: 27567705
[TBL] [Abstract][Full Text] [Related]
35. Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in human prostate cancer.
Xie M; Xie R; Xie S; Wu Y; Wang W; Li X; Xu Y; Liu B; Zhou Y; Wang T; Gao L; Pan T
Cell Biol Int; 2020 Oct; 44(10):2094-2106. PubMed ID: 32639616
[TBL] [Abstract][Full Text] [Related]
36. Both Ser361 phosphorylation and the C-arrestin domain of thioredoxin interacting protein are important for cell cycle blockade at the G1/S checkpoint.
Kamitori K; Yamaguchi F; Dong Y; Hossain A; Katagi A; Noguchi C; Hirata Y; Tsukamoto I; Hatano N; Tokuda M
FEBS Open Bio; 2018 Nov; 8(11):1804-1819. PubMed ID: 30410860
[TBL] [Abstract][Full Text] [Related]
37. Thioredoxin Interacting Protein (TXNIP) Is Differentially Expressed in Human Tumor Samples but Is Absent in Human Tumor Cell Line Xenografts: Implications for Its Use as an Immunosurveillance Marker.
Schröder J; Schumacher U; Böckelmann LC
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081035
[TBL] [Abstract][Full Text] [Related]
38. Histone methyltransferase inhibitor UNC0642 promotes breast cancer cell death by upregulating TXNIP-dependent oxidative stress.
Singh J; Sah B; Shen Y; Liu L
Chem Biol Interact; 2023 Nov; 385():110720. PubMed ID: 37748637
[TBL] [Abstract][Full Text] [Related]
39. Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition.
Spaeth-Cook D; Burch M; Belton R; Demoret B; Grosenbacher N; David J; Stets C; Cohen D; Shakya R; Hays JL; Chen JL
Oncotarget; 2018 Nov; 9(86):35676-35686. PubMed ID: 30479697
[TBL] [Abstract][Full Text] [Related]
40. The role of HER-2 in Breast Cancer.
Ishikawa T; Ichikawa Y; Shimizu D; Sasaki T; Tanabe M; Chishima T; Takabe K; Endo I
J Surg Sci; 2014 Dec; 2(1):4-9. PubMed ID: 25679012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
